Vyera Pharmaceuticals competitors

Yvonne Greenstreet is a COO at ALNYLAM PHARMACEUTICALS, INC..

Nick Leschly has served as our chief bluebird since September 2010. Formerly, Nick was a partner and founding member of Third Rock Ventures in 2007. Nick played an integral role in the overall formation, development and business strategy of several of Third Rock’s portfolio companies, including Agios Pharmaceuticals, Inc. and Edimer Pharmaceuticals, Inc. Prior to joining Third Rock, he worked at Millennium Pharmaceuticals, leading several early-stage drug development programs and served as the product leader for VELCADE. Nick also founded and served as chief executive officer of MedXtend Corporation. He received his B.S. in molecular biology from Princeton University and his MBA from Wharton Business School. He currently serves as a board member of the Biotechnology Innovation Organization (BIO) and Synlogic Therapeutics.

Richard Jeong Gu is a Board Member at NEUROBO PHARMACEUTICALS INC and Board Member at NeoImmuneTech, Inc.. He has worked as President/CEO/Interim CFO/Treasurer/Secy at NEUROBO PHARMACEUTICALS INC and Co-President/CEO at NeoImmuneTech, Inc.. Richard studied at University of Edinburgh and SNU Awards.

Mark L. Baum is the founder and CEO of Imprimis Pharmaceuticals whose mission is to provide patients and physicians with innovative and affordable ophthalmic drugs in the ocular surgery, glaucoma, and dry eye disease markets. He is also a founder and board member of Eton Pharmaceuticals and Surface Pharmaceuticals, as well as a board member and chairman of the audit committee of Ideal Power. He was named by Ernst & Young LLP as the 2017 Entrepreneur of the Year™ in the life sciences category for the San Diego region. Prior to Imprimis, as the founder of TBLF, LLC, a private investment fund, He made more than 200 investments into more than 40 private and public companies. In 1999, He founded YesRx, an HIV-focused pharmacy business. He's advocacy for drug pricing and accessibility issues has been reflected as an Op-Ed contributor for the Wall Street Journal and through appearances on CBS, CNN, MSNBC, Fox Business, Bloomberg and Al Jazeera. He is a 1995 cum laude graduate of The University of Texas at Arlington and a 1997 graduate of California Western School of Law.

Robert M. Davis is corporate vice president and president of Baxter's Medical Products business. In this position, Davis oversees a range of products used in the delivery of fluids and drugs to patients, and in the treatment of end-stage kidney disease. Davis took on his current role in October 2010. Prior to this role, Davis served as corporate vice president and president of Baxter's Renal business. He served as corporate vice president and chief financial officer from 2006 through May 2010, and as treasurer from 2004 through 2006. Davis joined Baxter as treasurer in November 2004 from Eli Lilly and Company, where he served in numerous positions of increasing responsibility over 14 years. Davis currently serves on the Board of Trustees for Rush University Medical Center and also serves as a member of the Finance Committee. He also is a member of the Board of Directors of AdvaMed.

Reshma Kewalramani (born 1973), is the president and chief executive officer of Vertex Pharmaceuticals, a biotechnology company based in Boston, Massachusetts, as of April 1, 2020. She is the first female CEO of a large US biotech company. She was previously the chief medical officer and vice president of global medicines development and medical affairs at Vertex.

Stéphane Bancel (born 1972) is a French billionaire businessman. He is the chief executive officer (CEO) and a 9% owner of Moderna, an American biotechnology company.

Mr. Jacobs is President and Chief Executive Officer for Harmony Biosciences. He joined Harmony from Teva Pharmaceuticals, where he held leadership roles as Senior Vice President and General Manager of the Respiratory Business Unit, Senior Vice President of Commercial Operations in North America and General Manager of Teva in Canada. Prior to joining Teva, he held positions of increasing scope and responsibility at major pharmaceutical companies, including Cephalon, Wyeth and Pfizer. Mr. Jacobs has over 25 years of commercial experience across multiple therapeutic areas, including CNS, Sleep Disorders, Pain Care and Respiratory, as well as rare disease and other specialty markets. His demonstrated expertise in developing market-leading commercial strategies, major product launches and building and leading highly effective teams and organizations has helped to shape Harmony’s positive culture of compassion for patients and passion for the business. He holds a bachelor’s degree in business and a Master of Business Administration in marketing from the State University of New York.